323 results about "Immune rejection" patented technology

The invention provides a recombinant XVII type collagen and application thereof, and relates to the technical field of protein engineering. The novel recombinant human XVII type collagen is obtained by optimizing and screening collagen structural domain sequences of the human XVII type collagen and then combining the sequences. The recombinant human XVII type collagen is consistent with the corresponding part of the amino acid sequence of the human XVII type collagen, does not generate immunological rejection when being applied to a human body, and can be widely applied to the industries of surgical medical treatment and medical beauty. In addition, the recombinant human XVII type collagen is high in stability, and the problem of protein degradation in the process of expressing recombinant protein by pichia pastoris can be avoided. In addition, the recombinant human XVII type collagen also has the effects of high biological activity, high biological safety, promotion of cell proliferation and differentiation and promotion of hair growth, and can be applied to the field of cosmetics or medicines as a functional component.

The invention belongs to the technical field of bioengineering, and particularly relates to recombinant III-type humanized collagen and application thereof. Area fragments with good hydrophilicity in a human III-type collagen alpha chain are selected and sequentially connected to serve as expression protein, the amino acid sequence is 100% identical to that of a corresponding part of natural human III-type collagen, and immunological rejection cannot be generated when the human III-type collagen is applied to a human body. According to the invention, the screened new III-type humanized collagen sequence is transferred into pichia pastoris for recombinant expression, the prepared recombinant III-type humanized collagen has the advantages of strong stability, high expression quantity and good hydrophilicity, and meanwhile, the recombinant III-type humanized collagen also has obvious effects of promoting cell proliferation and cell adhesion.

The invention provides recombinant VIII type humanized collagen and application thereof, and the recombinant VIII type humanized collagen is of a triple helix structure, has good cell adhesion activity, does not generate immunological rejection and anaphylactic reaction when being applied to a human body, is a brand new human body synthetic biological material, and has good application prospects.

The invention provides a micromolecular recombinant XVII type collagen as well as a preparation method and application thereof, and relates to the technical field of protein engineering. The novel recombinant human XVII type collagen is obtained by optimizing and screening a plurality of spiral region sequences such as a collagen structural domain, a C-terminal region and a middle region of the human XVII type collagen. The amino acid composition of the recombinant XVII type collagen is consistent with that of a natural collagen alpha1 chain, immunological rejection is not generated when the recombinant XVII type collagen is applied to a human body, the recombinant XVII type collagen can be widely applied to surgical medical treatment and medical beauty industries, the molecular weight of the collagen is small, efficient secretion soluble expression in eukaryotic host cells such as pichia pastoris can be achieved, and the recombinant XVII type collagen has a good application prospect. And industrial large-scale production is carried out. According to the present invention, the verification results show that the micromolecular recombinant XVII type collagen further has basement membrane anti-aging activity, wherein the basement membrane anti-aging activity specifically comprises the improvement of the expression levels of the IV type collagen, the VII type collagen and the XVII type collagen;

The present invention relates to a method for constructing an eight-gene-edited xenogeneic organ transplantation donor pig, belonging to the field of animal biotechnology. In the wild-type porcine fetal fibroblast cell line, the GGTA1, β4GalNT2, and CMAH genes are knocked out by using the CRISPR / Cas9 gene editing technology, and the humanized genes of hCD39, hCD46, hCD55, hCD59, and hTBM are transfected. Combining with somatic cell cloning technology, GTKO / β4GalNT2KO / CMAHKO / hCD39 / hCD46 / hCD55 / hCD59 / hTBM eight-gene-edited cloned pigs are constructed. Further, through genotype, mRNA, protein expression identification and functional analysis, eight-gene-edited xenogeneic organ transplantation donor pigs are obtained. The present invention solves the technical problems of high production difficulty, low efficiency, and low survival rate of donor pigs for multi-gene-edited xenogeneic organ transplantation, and maximally solves the common problems of immune rejection reaction and complement dysregulation faced during xenogeneic organ transplantation, laying a foundation for more targeted development of donor pigs suitable for different tissue and organ xenotransplantation, and having important value for promoting the clinical transformation of xenogeneic organ transplantation.

The invention discloses an engineered autologous tumor tissue scaffold and application thereof, and the engineered autologous tumor tissue scaffold is prepared by performing specific treatment on autologous tumor tissue to induce immunogenic cell death of the tumor tissue, and then sequentially performing freezing and drying steps; the engineered autologous tumor tissue scaffold can be used for loading dendritic cells and constructing personalized tumor vaccines. According to the stent, autologous tumor tissue is adopted, so that a specific and comprehensive tumor antigen pedigree is reserved, and multi-epitope immunostimulation is provided; and meanwhile, excellent biocompatibility is ensured, the immunological rejection risk is reduced, and relatively high safety is ensured.

The invention relates to an in-situ osteochondral regeneration and repair scaffold and a preparation method thereof, the in-situ osteochondral regeneration and repair scaffold prepared by the method comprises a cartilage layer, a connecting layer and a subchondral bone layer, the porosity of the cartilage layer is not less than 85%, the Young modulus is 6-13KPa, and the aperture is 130-140 [mu] m; the porosity of the connecting layer is not lower than 95%, the Young modulus is 4-19 KPa, and the aperture is 50-120 [mu] m; the porosity of the subchondral bone layer is not lower than 95%, the Young modulus is 4-19 KPa, and the aperture is 300-400 microns. The in-situ osteochondral regeneration and repair scaffold prepared by the method has good biocompatibility, is beneficial to attachment, migration and proliferation of cartilage cells and bone marrow mesenchymal stem cells, does not cause immunological rejection, provides a better scaffold environment for repair after osteochondral implantation, and has a good application prospect in the field of in-situ osteochondral regeneration and repair, and experiments prove that the in-situ osteochondral regeneration and repair scaffold has a good application prospect in the field of in-situ osteochondral regeneration and repair. The in-situ osteochondral regeneration and repair scaffold does not affect cell migration; animal experiments prove that the in-situ osteochondral regeneration and repair scaffold has a good repair effect on rat osteochondral defects.

The invention relates to a construction method of a four-gene editing xenogenic organ transplantation donor pig, and belongs to the technical field of animal biology. In a wild type pig fetal fibroblast cell line, a GGTA1 gene is knocked out by utilizing a CRISPR / Cas9 gene editing technology, three humanized genes of hCD39, hCD55 and hTBM are transferred, a GTKO / hCD39 / hCD55 / hTBM four-gene editing cloned pig is constructed in combination with a somatic cell nucleus transplantation technology, and four-gene editing xenogenic organ transplantation donor pigs are further obtained in batches through genotype identification and protein function phenotype analysis. According to the invention, the common problem of antigen-antibody mediated immunological rejection in a pig-human xenograft process is solved to a certain extent, and a foundation is laid for further research and development of donor pigs suitable for xenograft of organs / tissues such as heart, kidney, liver, skin and the like; the method has an important prospect for carrying out pre-clinical research on pig-non-human primate xenogeneic organ transplantation and clinical application of pig-human xenogeneic organ transplantation.

The invention provides sgRNA for targeting and guiding nuclease to efficiently cut an HLA-DRA gene, a method for modifying a CAR-T cell by using the sgRNA, and a related gene editing system, reagent and kit. According to the CAR-T cell, the immunogenicity is greatly reduced, the risk of graft versus host disease and immunological rejection can be effectively reduced, and meanwhile the killing capacity of tumor cells of the CAR-T cell is not affected.

The invention provides sgRNA for targeting and guiding nuclease to efficiently cut a B2M gene, a method for modifying cells by using the sgRNA, and a related gene editing system, reagent and kit. The cells produced by the invention greatly reduce the immunogenicity, can effectively reduce the risk of graft versus host disease and immunological rejection, and does not affect the killing ability of the cells to tumor cells.

The invention relates to a method for carrying out gene editing on a TRAC gene locus. Specifically, the invention provides sgRNA targeting and guiding nuclease to efficiently cut a TRAC gene, a method for modifying a CAR-T cell by using the sgRNA, the CAR-T cell obtained by the method, and a related gene editing system, reagent and kit. According to the CAR-T cell, the immunogenicity is reduced, the risk of graft versus host disease and immunological rejection can be effectively reduced, and meanwhile the killing capacity of tumor cells of the CAR-T cell is not affected.

The invention relates to spatial information compression and delivery, and belongs to the field of information delivery. The invention provides a device for delivering event information to a nervous system after spatial compression and a method for fine regulation and control of large-scale neurons. The device comprises an imaging system for respectively coding event information into a plurality of patterns, and a plurality of optic nervous systems for regulating and controlling the activity of a single neuron in a nervous system by using a minimum information unit coded in the patterns, and the pattern projection system is used for respectively projecting the plurality of patterns coded by the imaging system to each optic nerve system. According to the device and the method, the problems that an existing neural electrode is low in information transmission efficiency, immunological rejection exists between the neural electrode and a nervous system, and nervous tissues are mechanically damaged are solved, fine regulation and control of all neurons in a large-scale neuron cluster are achieved, and high-bandwidth input of multi-dimensional event information to a whole brain area of the nervous system is achieved.

Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and / or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and / or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.

The invention discloses an anti-parvovirus canine-mouse chimeric antibody, and belongs to the field of gene engineering, the chimeric antibody comprises a heavy chain variable region, a light chain variable region, a heavy chain constant region and a light chain constant region, the heavy chain variable region and the light chain variable region are mouse-derived fragments, and the heavy chain constant region and the light chain constant region are canine-derived fragments; the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.2, and the amino acid sequence of the light chain variable region is as shown in SEQ ID No.4. The canine-mouse chimeric antibody has broad-spectrum high neutralization activity on various subtypes of CPV in vitro, the immunological rejection of a mouse antibody in a canine body is reduced, and the canine infected by CPV-2c can be effectively treated by using the canine-mouse chimeric antibody.

The present disclosure features allogeneic modified cells (e.g., T- or NK-cells) having increased persistence, increased resistance to immune rejection, and / or decreased risk of eliciting a host-versus-graft reaction, or a combination thereof. Methods for producing and using the same are also provided.

The invention provides an acellular matrix particle freeze-dried implant as well as a preparation method and application thereof, and belongs to the technical field of soft tissue filling materials. The acellular matrix particle freeze-drying implant consists of an acellular matrix, a suspending aid and a freeze-drying protective additive, wherein the mass ratio of the acellular matrix to the suspending aid to the freeze-drying protective additive is (0.5-10): (0.5-10): (0.5-6); and the particle size of the cell matrix freeze-drying implant is 10-1000 [mu] m. The acellular matrix particle freeze-dried implant retains a natural three-dimensional structure and natural active components, and reduces immunological rejection caused by raw material sources after clinical use of an injection product; the composition is suitable for being injected to irregular defect positions for filling and repairing, is injected to a subcutaneous corium layer deep layer to a subcutaneous superficial layer to repair moderate to severe wrinkles or wrinkles, and has a good repairing effect.

The invention discloses application of a 3D hypoxia mesenchymal stem cell derived exosome preparation in preparation of an immune cell proliferation inhibitor or a medicine for treating acute myocardial infarction, belongs to the technical field of biology, and solves the problems of low cell survival rate and immunological rejection in application of a cell treatment method in the prior art. The 3D hypoxia mesenchymal stem cell derived exosome is used as a medium for treating acute myocardial infarction, and the problem of immunological rejection can be solved.

The invention relates to the technical field of biomedical material modification, in particular to a sulfhydrylation biocompatible polymer derivative, a preparation method thereof, extracellular matrix imitating injectable in-situ cross-linked hydrogel and application thereof. According to the invention, a pre-acylation strategy is firstly carried out on the biocompatible polymer containing both amino and carboxyl, so that a three-dimensional cross-linked byproduct formed by coupling of self amido bonds is avoided, meanwhile, the number of side chain carboxyl for sulfhydrylation modification is increased, and the accurate and adjustable pre-acylation rate can optimize the physical and chemical properties of the derivative; meanwhile, a disulfide bond is used as a protective precursor, active sulfydryl is introduced through amido bond coupling, self-oxidation of the active sulfydryl in the reaction process is avoided, sulfydryl activity is guaranteed, hydrazine-containing reagents are avoided, safety is further improved, virus residues and immunological rejection risks are avoided, universality is high, and the application prospect is wide; and in combination with a high-concentration preparation method, the method has the advantage of large-scale production, and further widens the industrial application potential.

The invention relates to the technical field of cartilage construction, in particular to an injectable tissue engineering cartilage in-vitro construction method which comprises the following steps: S1, micro-ecological cartilage environment simulation design; s2, self-assembly of the stent and space-time guidance; and S3, constructing a reversible tissue-degradation platform. A tissue engineering system highly simulating a natural cartilage microenvironment is constructed through the technology of combining bionic design and dynamic regulation and control, the proliferation activity and functional differentiation efficiency of cartilage cells can be effectively improved, and meanwhile, by means of intelligent support design and a growth factor delivery system, the tissue engineering system can be applied to the field of cartilage tissue engineering. Accurate release of factors and cell navigation are realized; the dynamic repair technology is combined with the non-contact mechanical stimulation and immune regulation strategy, it is ensured that transplanted tissue can be continuously generated and fully integrated with host tissue, the problems of immunological rejection or insufficient stent degradation and the like are solved, the success rate and long-term stability of cartilage regeneration are remarkably improved, and the method has good clinical application prospects.

The invention relates to the technical field of culture media, in particular to a serum-free complete culture medium for human umbilical cord mesenchymal stem cells and a preparation method thereof.The serum-free complete culture medium takes DMEM / F12 as a basic culture medium and is matched with UltraGRO-Advanced, a penicillin-streptomycin double-antibody solution, a recombinant human epidermal growth factor and a basic fibroblast growth factor, and the serum-free complete culture medium for the human umbilical cord mesenchymal stem cells is obtained. The serum-free complete culture medium can replace a serum culture medium in a conventional culture system of mesenchymal stem cells, the characteristics of normal adherence, good growth state and stem cells of the cells are kept, the serum-free complete culture medium reduces the risks of heterologous contamination and immunological rejection to the maximum extent, the added components capable of promoting cell growth and the content can be determined and controlled, and the culture medium is suitable for large-scale popularization and application. The use is safer.

The invention discloses a preparation method and application of collagen derivative and polysaccharide substance compounded self-gel hemostatic powder, and relates to the field of biomedical materials. Aminated collagen derivatives and aldehyde polysaccharide substances are subjected to a Schiff base reaction through amino groups and aldehyde groups; further obtaining the Schiff base cross-linked aminated collagen derivative-aldehyde polysaccharide hydrogel, freeze-drying, and grinding into powder, so as to obtain the self-gel hemostatic powder. The self-gel hemostatic powder disclosed by the invention forms hydrogel in a wound tissue for adhesion and sealing, so that rapid hemostasis is realized, postoperative adhesion at the wound tissue is avoided, and healing of a wound is facilitated; after hemostasis is completed, the self-gel powder can be dissociated and removed from the tissue surface, and the risk that thrombus is formed and immunological rejection is caused is reduced; after hemostasis is completed, the hemostasis powder can be metabolized and absorbed by a human body along with thrombus, so that the residue of the hemostasis powder in the body is reduced, and the safety is improved.

The invention discloses a method for designing a bionic femoral stent based on fusion of a VT structure and a TPMS structure, and belongs to the technical field of bionic bone stents. The method comprises the following steps: respectively creating a Diamond unit homogeneous porous structure and a VT porous structure; and creating a Ramp fusion function, substituting the homogeneous porous structure of the Diamond unit and the Ramp fusion function into a Mix instruction, and then sequentially substituting the VT porous structures into the Mix instruction to generate a fusion model. The homogeneous porous structure of the Diamond unit and the VT porous structure are subjected to radial smooth fusion, smooth connection is realized at the fusion position, the service life of the porous structure serving as the bionic bone scaffold is shortened, the smooth surface of the D unit and the periodic structure uniformly conduct stress, the rounded Thiessen polygonal structure further disperses stress, and the stress dispersion and synergistic effects are achieved. The bionic femoral stent constructed by the invention can simulate natural bones, promote cell adhesion, proliferation and differentiation, and optimize transportation of nutrient substances and metabolic wastes. And the smooth fusion interface reduces cell damage and reduces immunological rejection.

The invention relates to the technical field of biological materials, in particular to a local anticoagulation acellular bone matrix composite material and a preparation method thereof.The preparation method comprises the following steps that S1, bone tissue is obtained and treated, and an acellular bone matrix is prepared; s2, mixing an anticoagulant with the acellular bone matrix to form an anticoagulant compound; s3, mixing the anticoagulant compound with a biocompatible carrier to form a final composite material; and S4, preparing the composite material into an implant or a stent with a required shape through a molding and curing process. By arranging the acellular bone matrix, the natural structure and biological activity of the bone matrix are reserved to the maximum extent, and meanwhile, all cell components are removed, so that immunogenicity and pathogen transmission are reduced; by adding the anticoagulant, discomfort can be reduced after the local anticoagulant acellular bone matrix composite material is implanted into a human body, and the problems that in the prior art, an acellular bone matrix has the blood coagulation risk, and incompletely-treated bone tissue has immunological rejection are solved.

Provided herein, among other things, is a cytotoxic immune cell (e.g., a cytotoxic T cell) that expresses an engineered immune receptor (such as a CAR or TCR) whose cytotoxicity within the tumor microenvironment is enhanced by a pro-inflammatory protein that is induced only when the cell binds to either a tissue-specific or cancer-associated antigen. As such, the present cells can be used for the treatment of cancers that are associated with solid tumors.

The invention provides a fat acellular matrix hydrogel material and a preparation method thereof. The fat freeze-dried powder is subjected to decellularization, digestion, acid-base balance regulation and gelation to prepare the fat freeze-dried powder. According to the method disclosed by the invention, a chemical decellularization method that liquid nitrogen freeze crushing is combined with 0.5% SDS and 1% Triton X-100 compound decellularization liquid is adopted, and fat is further removed through isopropyl alcohol treatment; adipose tissues can be uniformly crushed into powder through liquid nitrogen freezing and crushing, the action area of decellularization liquid is increased, the thoroughness of decellularization is remarkably improved, and the problem of fat or decellularization liquid residue can be avoided through multiple times of pure water and alcohol replacement treatment; according to the method, the mild decellularization solution is adopted for treatment for 12 hours, so that damage to key components of the matrix due to high-concentration chemical reagents and long-time action is effectively avoided. According to the method disclosed by the invention, immunological rejection caused by cell residues and adverse effects of fat residues on biocompatibility and mechanical properties can be remarkably reduced, so that the clinical applicability of the hydrogel is improved.

The invention belongs to the technical field of biological carriers, and particularly relates to a preparation method and application of an exosome ferulic acid nano-composite. The invention provides a way for preparing ferulic acid nano-particles by using exosomes, and particularly relates to a preparation process for forming a nano-composite by using ferulic acid and stress yeast exosomes generated by stimulation. The preparation method of the exosome ferulic acid nano-composite provided by the invention has the advantages of high safety, low immunological rejection, high cell fusion degree, high entrapment rate and good stability. Besides, the selected stress yeast exosome can effectively protect and enhance the anti-inflammatory and anti-oxidation effects of ferulic acid, so that the prepared exosome ferulic acid nano-composite has relatively strong anti-inflammatory, anti-oxidation and repair effects, and has a good application prospect in the field of cosmetics or medicines.

The invention relates to the technical field of biology, and particularly discloses polypeptide, recombinant XIX type humanized collagen and application of the recombinant XIX type humanized collagen. The amino acid sequence of the polypeptide comprises n repetitive units; the repetitive unit comprises any one of the following amino acid sequences or variant sequences thereof: (1) an amino acid sequence as shown in any one of SEQ ID NO.1-2; (2) an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence as shown in any one of SEQ ID NO.1-2; (3) a variant sequence obtained by performing mutation of one or more amino acid residues on the amino acid sequence as shown in any one of SEQ ID NO.1-2; wherein n is an integer greater than or equal to 1. The polypeptide provided by the invention has a collagen triple helix structure, has good cell adhesion activity, can carry out functions of human collagen, is free of immunological rejection and anaphylactic reaction, and can be used in various fields of cartilage repair, biological dressing, tissue filling and the like.

The present invention relates to a novel anti-CD40 antibody and use thereof and, more specifically, to a novel anti-CD40 antibody and use thereof, wherein the antibody comprises a complementarity determining region of a specific sequence and exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling. The novel anti-CD40 antibody of the present invention exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling, and thus can be widely used as a preparation for preventing or treating various diseases, such as autoimmune diseases and chronic inflammatory diseases, and as a preparation for inhibiting immune rejection at the time of transplantation.